Illumina Inc. Stock
€98.20
Your prediction
![Hi, I am the sharewise BeanCounterBot. I am digging through tons of financial data to give you a brief summary. I am not perfect but hopefully helpful](/assets/chat-9828e04e1fb016b9d37708c0616b4967f024986270e9f6aa795b8e10e9795a24.png)
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Illumina
sharewise wants to provide you with the best news and tools for Illumina, so we directly link to the best financial data sources.
Financials
News
![U.S. Rep. Thomas Kean Jr. Just Bought Illumina Stock and Sold Nike Stock. Should You Do the Same?: https://g.foolcdn.com/editorial/images/779220/united-states-capitol-building-us-congress-washington-dc-capital-1200x743-b29a47e.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK3F5YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--18e48d1043966fa7cb6a7fd05f276095280a9bd7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/united-states-capitol-building-us-congress-washington-dc-capital-1200x743-b29a47e.jpg?locale=us)
U.S. Rep. Thomas Kean Jr. Just Bought Illumina Stock and Sold Nike Stock. Should You Do the Same?
On April 19, U.S. Rep. Thomas Kean Jr., R-N.J., bought shares of Illumina (NASDAQ: ILMN) and sold shares of Nike (NYSE: NKE), according to a May 31 filing. Although it's unclear exactly how many
![Why Illumina Stock Zoomed Higher on Thursday: https://g.foolcdn.com/editorial/images/770227/medical-professional-working-at-a-computer-terminal.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeXRkYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b796823963566c1ce10d8ed21676fcd2f5187324/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/medical-professional-working-at-a-computer-terminal.jpg?locale=us)
Why Illumina Stock Zoomed Higher on Thursday
A legal opinion on the other side of Planet Earth put some juice into Illumina's (NASDAQ: ILMN) stock on Thursday. The gene-sequencing specialist saw its share price rise by over 3%, against the S&P
![Why Illumina Stock Mashed the Market on Monday: https://g.foolcdn.com/editorial/images/766928/medical-professional-holding-dollar-sign-paperweight.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3BBYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7d28fe20fe499078f48221de54d1d3389df276ba/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/medical-professional-holding-dollar-sign-paperweight.jpg?locale=us)
Why Illumina Stock Mashed the Market on Monday
Gene-sequencing stock Illumina (NASDAQ: ILMN) was a standout in the biotech sector Monday, with its share-price rise convincingly beating the S&P 500 index. Investors were cheered by a stock buy
![Why Illumina Rallied 36.6% in December: https://g.foolcdn.com/editorial/images/760588/scientist-altering-dna-genome-project.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL1FGYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a8fd46e1abb2cf6f71f576946052a35b40f54f1e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientist-altering-dna-genome-project.jpg?locale=us)
Why Illumina Rallied 36.6% in December
Shares of gene sequencing leader Illumina (NASDAQ: ILMN) rallied 36.6% in December, according to data from S&P Global Market Intelligence.
Investors might not be quite so excited, as Illumina